-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Drug Screening Assays, Antitumor are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Drug Screening Assays, Antitumor.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.
Rad R, Cadiñanos J, Rad L, Varela I, Strong A, Kriegl L, Constantino-Casas F, Eser S, Hieber M, Seidler B, Price S, Fraga MF, Calvanese V, Hoffman G, Ponstingl H, Schneider G, Yusa K, Grove C, Schmid RM, Wang W, Vassiliou G, Kirchner T, McDermott U, Liu P, Saur D, Bradley A
(2013) Cancer Cell 24: 15-29 - ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ
(2012) J Clin Oncol 30: 863-70 - Inhibition of pancreatic adenocarcinoma cell growth by lovastatin.
Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC
(1992) Gastroenterology 103: 982-9 - Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
Wang J, Mouradov D, Wang X, Jorissen RN, Chambers MC, Zimmerman LJ, Vasaikar S, Love CG, Li S, Lowes K, Leuchowius KJ, Jousset H, Weinstock J, Yau C, Mariadason J, Shi Z, Ban Y, Chen X, Coffey RJC, Slebos RJC, Burgess AW, Liebler DC, Zhang B, Sieber OM
(2017) Gastroenterology 153: 1082-1095 - Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction.
Vanderburgh J, Hill JL, Gupta MK, Kwakwa KA, Wang SK, Moyer K, Bedingfield SK, Merkel AR, d'Arcy R, Guelcher SA, Rhoades JA, Duvall CL
(2020) ACS Nano 14: 311-327 - Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, Sheets M, St Martin T, Karp R, van Kalken D, Chaturvedi P, Niu D, Nacht M, Petter RC, Westlin W, Lin K, Jaw-Tsai S, Raponi M, Van Dyke T, Etter J, Weaver Z, Pao W, Singh J, Simmons AD, Harding TC, Allen A
(2013) Cancer Discov 3: 1404-15 - Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL
(2012) Proc Natl Acad Sci U S A 109: 2718-23 - The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.
Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA
(2012) Cancer Res 72: 3901-5 - Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB
(1994) Cancer Res 54: 4703-9 - Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL
(1999) Clin Cancer Res 5: 35-42 - Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.
Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG
(2010) Clin Cancer Res 16: 3193-204 - Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.
Weng L, Ziliak D, Im HK, Gamazon ER, Philips S, Nguyen AT, Desta Z, Skaar TC, Flockhart DA, Huang RS, Consortium on Breast Cancer Pharmacogenomics (COBRA)
(2013) Ann Oncol 24: 1867-1873 - Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.
Karlström A, Boyd KL, English BK, McCullers JA
(2009) J Infect Dis 199: 311-9 - Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.
Walsh AJ, Cook RS, Skala MC
(2017) J Nucl Med 58: 1367-1372 - Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M, Oost TK, Belli BA, Ding H, Joseph MK, Kunzer A, Martineau D, McClellan WJ, Mitten M, Ng SC, Nimmer PM, Oltersdorf T, Park CM, Petros AM, Shoemaker AR, Song X, Wang X, Wendt MD, Zhang H, Fesik SW, Rosenberg SH, Elmore SW
(2007) J Med Chem 50: 641-62 - Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
Lavieri RR, Scott SA, Selvy PE, Kim K, Jadhav S, Morrison RD, Daniels JS, Brown HA, Lindsley CW
(2010) J Med Chem 53: 6706-19 - Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.
Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ
(2012) J Med Chem 55: 2287-300 - Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW
(2006) J Med Chem 49: 1165-81 - Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B, Chen W, Orr BA, Spitsbergen JM, Jia S, Eden CJ, Henson HE, Taylor MR
(2015) Mol Cancer 14: 18 - Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Psallidas I, Karabela SP, Moschos C, Sherrill TP, Kollintza A, Magkouta S, Theodoropoulou P, Roussos C, Blackwell TS, Kalomenidis I, Stathopoulos GT
(2010) Mol Cancer 9: 56 - The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.
Pozzi A, Popescu V, Yang S, Mei S, Shi M, Puolitaival SM, Caprioli RM, Capdevila JH
(2010) J Biol Chem 285: 12840-50 - Progress toward the total synthesis of lucentamycin A: total synthesis and biological evaluation of 8-epi-lucentamycin A.
Daniels RN, Melancon BJ, Wang EA, Crews BC, Marnett LJ, Sulikowski GA, Lindsley CW
(2009) J Org Chem 74: 8852-5 - Assessing cardiac safety in oncology drug development.
Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF
(2019) Am Heart J 214: 125-133 - Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design.
Hargrove TY, Friggeri L, Wawrzak Z, Sivakumaran S, Yazlovitskaya EM, Hiebert SW, Guengerich FP, Waterman MR, Lepesheva GI
(2016) J Lipid Res 57: 1552-63 - Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA
(2006) Mol Cancer Res 4: 521-8 - Inhibitors of HER2/neu (erbB-2) signal transduction.
Arteaga CL, Chinratanalab W, Carter MB
(2001) Semin Oncol 28: 30-5 - A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs.
Xie J, Wang C, Virostko J, Manning HC, Pham W, Bauer J, Gore JC
(2013) Chembiochem 14: 1494-503 - Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.
Li B, Flaveny CA, Giambelli C, Fei DL, Han L, Hang BI, Bai F, Pei XH, Nose V, Burlingame O, Capobianco AJ, Orton D, Lee E, Robbins DJ
(2014) PLoS One 9: e101969 - Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP
(2013) PLoS One 8: e80060 - BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner.
Lau KS, Zhang T, Kendall KR, Lauffenburger D, Gray NS, Haigis KM
(2012) PLoS One 7: e41343 - Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM
(1991) J Urol 146: 171-6 - The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D
(2011) Cancer Biol Ther 12: 484-93 - Total synthesis and biological evaluation of the marine bromopyrrole alkaloid dispyrin: elucidation of discrete molecular targets with therapeutic potential.
Kennedy JP, Brogan JT, Lindsley CW
(2008) J Nat Prod 71: 1783-6 - High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model.
Pink D, Luhrs KA, Zhou L, Schulte W, Chase J, Frosch C, Haberl U, Nguyen V, Roy AI, Lewis JD, Zijlstra A, Parseghian MH
(2015) Sci Rep 5: 15756 - Myostatin inhibits proliferation and insulin-stimulated glucose uptake in mouse liver cells.
Watts R, Ghozlan M, Hughey CC, Johnsen VL, Shearer J, Hittel DS
(2014) Biochem Cell Biol 92: 226-34 - Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Waterson AG, Stevens KL, Reno MJ, Zhang YM, Boros EE, Bouvier F, Rastagar A, Uehling DE, Dickerson SH, Reep B, McDonald OB, Wood ER, Rusnak DW, Alligood KJ, Rudolph SK
(2006) Bioorg Med Chem Lett 16: 2419-22 - High Throughput Screening for Colorectal Cancer Specific Compounds.
Xie J, Wang C, Gore JC
(2016) Comb Chem High Throughput Screen 19: 180-8
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
